Wed, Mar. 11, 12:47 PM
Nov. 7, 2014, 12:52 PM
Nov. 6, 2014, 12:47 PM
Nov. 6, 2014, 12:28 PM
- Solazyme (SZYM -50.2%) shares are cut in half after the maker of renewable energy products reports below consensus Q3 earnings and is tagged with multiple analyst downgrades.
- Baird lowers its rating on SZYM to Neutral from Outperform, seeing challenges in ramping its Moema facility and likely will no longer reach cash flow breakeven in 2015, which limits its ability to deploy capital for expansion efforts, Baird says as it cuts its share price target to $9 from $16.
- Shares also are downgraded to Market Perform at Pacific Crest, which says SZYM has failed to achieve its cost goals as it struggles to ramp its new Brazil plant, and will now operate at sub-scale in an effort to preserve cash.
Nov. 6, 2014, 9:14 AM
- Gainers: PLNR +74%. PESI +24%. SWIR +20%. MEET +13%. RVLT +11%. COT +11%. DATA +11%. ACAS +10%. NDLS +9%. KATE +8%. KATE +8%. WFM +9%. HZNP +6%. CECO +6%. DRYS +5%. TRUE +5%.
- Losers: AEZS -51%. SZYM -47%. SNMX -26%. GNW -24%. WWWW -22%. CSOD -19%. PHMD -17%. GERN -14%. MCP -12%. GNRC -11%. WAC -9%. QCOM -7%. Z -7%. PBR -5%.
Oct. 9, 2014, 12:46 PM
Jul. 30, 2014, 4:11 PM
May. 29, 2014, 9:39 AM
- Solazyme (SZYM +12.2%) surges at the open on news that its joint venture with Bunge (BG +1.1%) has successfully produced its first commercially saleable products on full-scale production lines at the renewable oils plant in Brazil.
- SZYM says both oil and encapsulated lubricant products have been manufactured; production is continuing and expected to reach nameplate capacity within the next 12-18 months.
- SZYM is now manufacturing products at three large scale facilities, including the 2K metric tons/year integrated facility in Peoria, Ill., the 20K/year Iowa facilities in Clinton/Galva and the 100K/year facility in Brazil.
May. 29, 2014, 9:12 AM
May. 7, 2014, 11:36 AM
- Amyris (AMRS -7.1%) falls sharply for a second straight day after StreetSweeper writes that the maker of renewable fuel compounds faces rough times ahead, citing "onerous deals, SEC filings and extreme insider selling."
- The pessimistic view comes ahead of Thursday's earnings report after the company reported worse-than-expected earnings numbers over each of the past five quarters.
- Combined with disappointing Q1 earnings from Renewable Energy Group (REGI -5.3%), several biofuel names are trading lower: CDTI -8.5%, SZYM -7.3%, KIOR -6.4%, SYNM -4.3%, BIOF -2%, FF -1.5%.
May. 6, 2014, 3:19 PM
- Solazyme (SZYM -3.8%) is sharply lower but has recovered from early 10% losses after reporting a bigger than expected Q1 loss and revenue of $12.4M fell short of estimates as its first commercial production in Brazil was pushed into the current quarter.
- CEO Jonathan Wolfson expects SZYM to begin commercial production at its Moema, Brazil, facility in the current quarter, after saying in November that would happen in Q1 rather than last year and reiterating the goal in February.
- Analysts estimate revenue of $115M in 2014 and $330M next year, but Q1 results don't appear to indicate a sufficient pick-up in production to reach those expectations.
Apr. 9, 2014, 5:39 PM
Feb. 27, 2014, 11:04 AM
- Solazyme (SZYM +6.6%) surges higher following Q4 earnings and a price target raise to $17 from $14 by Cowen analysts who see production volume ramping in the latter part of 2014.
- The firm says SZYM's quarterly loss was "essentially in line with [its] expectations” and due to higher expenses as the company ramps up production at its plant in Clinton, Iowa.
- Cowen says 2014 production at Clinton totaled ~500 metric tons, with three different oil-based products scaled up and a fourth underway; Mooema has completed most phases of its startup, as fermentation is running from seed train to 125K liter scale and 600K liter production fermenters should start up in March.
- Shares also may be enjoying some spillover from a surge in biofuel and ethanol names as Pacific Ethanol (PEIX +32.5%) reports favorable news (I, II): BIOF +85.7%, CDTI +9.8%, KIOR +9.5%, REX +2.5%.
Feb. 26, 2014, 5:37 PM
Jan. 31, 2014, 3:58 PM
- Solazyme (SZYM +31.5%) soars near 52-week highs after starting commercial-scale production at its algae-based industrial biotech platform in Iowa, but Raymond James' Pavel Molchanov thinks this may just be the beginning.
- The start-up at the Clinton plant was one of two major catalysts Molchanov was watching for; the next is the Moema plant in Brazil, expected later this quarter.
- Positive cash flow now becomes realistic in 2015, the analyst says: "While the ramp-up of production will certainly not be linear... we anticipate utilization rising to 50% in 4Q14. This translates into a four-fold increase in total revenue from 3Q13 to year-end 2014, with product sales jumping by an even larger amount (7x)."
Jan. 31, 2014, 12:46 PM
SZYM vs. ETF Alternatives
Solazyme Inc, along with its subsidiaries, is engaged in providing renewable oils and other bioproducts. It commercializes its products into target markets such as chemicals and fuels, nutrition, and skin and personal care.
Other News & PR